U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

Icon_funbox Celebrity Inventors

Penn Jillette of Penn and Teller fame has patented a "Hydro-Therapeutic Stimulator", which uses a hot tub for stimulation.

Newsletter  PatentStorm News

Make the Most of PatentStorm

See this month's Top Inventors and Most Cited Patents.

Stay on top of the latest patents by subscribing to an RSS feed.

Got questions? Ask a Patent Expert!

Registered users: Manage your profile, comments and alerts.

 

Search Results for method viral vaccines kistner

Results 1 - 40 of 81 - maximum of 1000 results shown
1      
NumberTitleIssue Date
20090060950Method for Producing Viral Vaccines
... ) United States Patent Application 20090060950 Kind Code A1 Kistner; Otfried ;   et al. March 5, 2009 Method for Producing Viral Vaccines Abstract The present invention provides a method for the manufacture of ... 		03/05/2009
20090047353CHANGING TH1/TH2 BALANCE IN SPLIT INFLUENZA VACCINES WITH ADJUVANTS
... from egg proteins). Inventors: O'Hagan; Derek; (Siena, IT) Correspondence Name and Address: NOVARTIS VACCINES AND DIAGNOSTICS INC. INTELLECTUAL PROPERTY R338, P.O. BOX 8097 Emeryville CA 94662-8097 US Assignee ... 		02/19/2009
20090202590INFLUENZA VACCINES EXTEMPORANEOUSLY ADSORBED TO ALUMINIUM ADJUVANTS
... inactivation include treatment with methylene blue, psoralen, carboxyfullerene (C60) or a combination of any thereof. Other methods of viral inactivation are known in the art, such as for example binary ethylamine, acetyl ethyleneimine, or ... 		08/13/2009
20090304739INFLUENZA VACCINES INCLUDING COMBINATIONS OF PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS
... inactivation include treatment with methylene blue, psoralen, carboxyfullerene (C60) or a combination of any thereof. Other methods of viral inactivation are known in the art, such as for example binary ethylamine, acetyl ethyleneimine, or ... 		12/10/2009
6136321Method of inactivating lipid-enveloped viruses
... exchange chromatography or gel filtration. However, all the methods described in the prior art for removal of non-ionic detergents from a solution are suitable. When using viral vaccines that, in particular, are administered orally, there is ... 		10/24/2000
20090304742INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION ADJUVANT
... emulsion and (ii) an aqueous preparation of an influenza virus antigen wherein the volume of a unit dose of the vaccine is less than 0.5 ml; or(c) (1) mixing substantially equal volumes of (i) an oil-in-water emulsion and (ii) an ... 		12/10/2009
5753489Method for producing viruses and vaccines in serum-free culture
... Patent 5,753,489 Kistner ,   et al. May 19, 1998 Method for producing viruses and vaccines in serum-free culture ... Ser. No. 08/338,761, filed Nov. 10, 1994, now abandoned, entitled "Method for Producing Influenza Virus and ... 		05/19/1998
5756341Method for controlling the infectivity of viruses
... United States Patent 5,756,341 Kistner ,   et al. May 26, 1998 Method for controlling the infectivity of viruses Abstract ... VERO cells, CV-1 cells, and LLC-MK2 cells. 25. A method according to claim 21, wherein said Influenza virus has ... 		05/26/1998
20090285854FROZEN STOCKPILING OF INFLUENZA VACCINES
... inactivation include treatment with methylene blue, psoralen, carboxyfullerene (C60) or a combination of any thereof. Other methods of viral inactivation are known in the art, such as for example binary ethylamine, acetyl ethyleneimine, or ... 		11/19/2009
20100010199MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS
... , methylene blue, psoralen, carboxyfullerene (C60), binary ethylamine, acetyl ethyleneimine, or combinations thereof. Non-chemical methods of viral inactivation are known in the art, such as for example UV light or gamma irradiation. [0133] ... 		01/14/2010
20090220541EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT FOR ADJUVANTING SPLIT INFLUENZA VACCINES
... a split influenza virus antigen and an oil-in-water emulsion, wherein the emulsion includes free surfactant in its aqueous phase. 2. The method of claim 1, wherein the influenza virus antigen is from a H1, H2, H3, H5, H7 or H9 influenza A ... 		09/03/2009
20090220545Adjuvant-Sparing Multi-Dose Influenza Vaccination Regimen
... inactivation include treatment with methylene blue, psoralen, carboxyfullerene (C60) or a combination of any thereof. Other methods of viral inactivation are known in the art, such as for example binary ethylamine, acetyl ethyleneimine, or ... 		09/03/2009
20090220546Adjuvanted influenza vaccines for pediatric use
... 1, wherein the virus antigen includes a subtype H3N2 influenza A strain antigen and the child receives one dose of vaccine. 8. The method of claim 1, wherein the virus antigen includes a subtype H1N1 influenza A strain antigen and the child ... 		09/03/2009
20090220544ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE
... of adjuvanted vaccines for protecting against influenza virus infection. BACKGROUND ART [0003]The current standard method for influenza virus growth in vaccine manufacture uses embryonated SPF hen eggs, with virus being purified from the egg ... 		09/03/2009
7195905Enveloped virus vaccine and method for production
... Patent 7,195,905 Kistner , et al. March 27, 2007 Enveloped virus vaccine and method for production Abstract The present ... cases presenting each year. Currently, there is no existing vaccine, and mosquito control programs have not had any ... 		03/27/2007
5698433Method for producing influenza virus and vaccine
... ( 1122 of 2822 ) United States Patent 5,698,433 Kistner ,   et al. December 16, 1997 Method for producing influenza virus and vaccine Abstract A method of producing an ... 		12/16/1997
7521220Production of vaccines
... vaccines derived thereof. This method eliminates the necessity of using whole chicken embryos for the production of Influenza vaccines. The method also provides for the continuous or batch-wise removal of culture media. As such, the present ... 		04/21/2009
7192759Production of vaccines
... wherein the modifications comprise glycosylation. A good example of a viral vaccine that has been cumbersome to produce in any reliable manner is influenza vaccine. The invention provides a method wherein the viral proteins comprise at least one of an ... 		03/20/2007
7527961Production of vaccines
... vaccines derived thereof. This method eliminates the necessity of using whole chicken embryos for the production of Influenza vaccines. The method also provides for the continuous or batch-wise removal of culture media. As such, the present ... 		05/05/2009
7550284Production of vaccines
... derived thereof. This method eliminates the necessity to use whole chicken embryos for the production of influenza vaccines. The method provides also for the continuous or batchwise removal of culture media. As such, the invention ... 		06/23/2009
6372223Influenza virus vaccine composition
... antigen content between 1 .mu.g and 5 .mu.g per dose and aluminum as an adjuvant as well as a method for its preparation. Inventors: Kistner; Otfried (Vienna, AT); Barrett; Noel (Klosterneuburg/Weidling, AT); Mundt; Wolfgang (Vienna, AT); ... 		04/16/2002
20090324645Production of vaccines
... modification, such as glycosylation. [0079]A good example of a viral vaccine that has been cumbersome to produce in any reliable manner is influenza vaccine. The invention provides a method wherein the viral proteins comprise at least one of an ... 		12/31/2009
20100021499CELL-BASED SYSTEMS FOR PRODUCING INFLUENZA VACCINES
... serves to prevent or attenuate any subsequent infection. When provided therapeutically, the attenuated or inactivated viral vaccine is provided upon the detection of a symptom of actual infection. The therapeutic administration of the ... 		01/28/2010
20060051747Production of vaccines
... modification, such as glycosylation. [0076] A good example of a viral vaccine that has been cumbersome to produce in any reliable manner is influenza vaccine. The invention provides a method wherein the viral proteins comprise at least one of an ... 		03/09/2006
20060063261Production of vaccines
... modification, such as glycosylation. [0079] A good example of a viral vaccine that has been cumbersome to produce in any reliable manner is influenza vaccine. The invention provides a method wherein the viral proteins comprise at least one of an ... 		03/23/2006
20070072207Production of vaccines
... wherein the modifications comprise glycosylation. A good example of a viral vaccine that has been cumbersome to produce in any reliable manner is influenza vaccine. The invention provides a method wherein the viral proteins comprise at least ... 		03/29/2007
20090081252DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES
... be subjected to new quality control. Assays of the invention are advantageously performed on the seed virus used for vaccine manufacture. [0053]In the methods of the invention, the cell lines used to grow influenza viruses may be cultured in any ... 		03/26/2009
20090004222Influenza Vaccination
... the invention avoids the pain associated with influenza vaccination, thereby increasing both patient comfort and compliance. [0007]Therefore the invention provides a method for immunising a patient against influenza virus, comprising the ... 		01/01/2009
20090304743Composition and Methods for Immunisation Using CD1D Ligands
... hybridisation assay and the total DNA Threshold.TM. system for measuring host cell DNA contamination of a human viral vaccine can be found in reference 164. [0152]Contaminating DNA can be removed during vaccine preparation using standard ... 		12/10/2009
6951752Method for large scale production of virus antigen
... Virus; Journal of Virological Methods; vol. 8, p. 63-71 (1984). Kistner et al., "Development of a novel influenza vaccine derived from a continuous cell ... Dev. Biol. Stand. 98: 23-37; Kistner et al., 1998. Vaccine 16:960-968; Kistner et al. 1999, Dev ... 		10/04/2005
6825027Method of production of purified hepatitis a virus particles and vaccine preparation
... antigen is not efficiently released into the culture supernatant and methods to concentrate the large volume are costly (Bishop et al., 1994 ... free medium can be one as described for example by Kistner et al. (1998. Vaccine 16: 960-968), Merten et al. (1994 ... 		11/30/2004
6855535Method of large scale production of Hepatitis A virus
... allow production of viral antigen using fermenter sizes of up to several thousand liters. Widell et al.(1984, J. Virol. Methods 8:63-71) ... serum- and protein free medium as described in Kistner et al. (1998. Vaccine 16:960-968) or WO 96/15231. For growth ... 		02/15/2005
7223595Use of purified trypsin for production of a biomass of cells and viral propagation
... , 2007 Use of purified Streptomyces griseus trypsin for production of a biomass of cells and viral propagation Abstract The present invention provides methods of isolation and purification of Streptomyces griseus trypsin (SGT) from PRONASE ... 		05/29/2007
6830917Method of isolation and purification of trypsin from pronase protease and use thereof
... minimal media known in the art, such as described in Kistner et al. (1998. Vaccine 16:960-968). Most preferably, the cells are grown in ... serum and protein free medium as described in Kistner et al. (1998. Vaccine 16: 960-968, WO 96/15231, or U.S. Pat. ... 		12/14/2004
5869035Methods and compositions for inducing complement destruction of tissue
... VIRUS INDEPENDENT VECTOR", incorporated herein by reference. In yet another preferred embodiment, the method includes the treatment to reduce the cytotoxicity of viral vectors such as Herpes simplex virus while retaining gene expression, by ... 		02/09/1999
7425336Canine influenza vaccines
...   ( 1848 of 2432 ) United States Patent 7,425,336 Minke ,   et al. September 16, 2008 Canine influenza vaccines Abstract The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be ... 		09/16/2008
7384642Canine influenza vaccines
... Equine/Jilin/1/89 (Eq/Jilin) (see, e.g., Webster & Thomas, Vaccine. 1993; 11(10):987-93), A/Equine/Alaska/1/91 (H3N8 ... commonly employed to make inactivated vaccines. These methods include but are not limited to formaldehyde treatment (O. Kistner et al idem ... 		06/10/2008
7556806Carbohydrate-based synthetic vaccines for HIV
... compounds that inactivate and/or bind the high-mannose oligosaccharide cluster. Compositions comprising these clusters, methods of using these clusters and compositions are disclosed. Inventors: Wang; Lai-Xi (Ellicott City, MD) ... 		07/07/2009
7060681Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids
... for drug delivery systems". Yonsei Med J. 2000 December;41(6):720 34. Jabbal-Gill I, Lin W, Kistner O, Davis S S, Illum L. "Polymeric lamellar substrate particles for intranasal vaccination". Adv Drug Deliv Rev. 2001. 51(1 3):97 111. Kawasaki, G. ( ... 		06/13/2006
20080241184CANINE INFLUENZA VACCINES
... Equine/Kentucky/1/81 (H3N8) (see, e.g., Olsen et al., Vaccine. 1997 July; 15(10):1149-56, Morley et al. ... commonly employed to make inactivated vaccines. These methods include but are not limited to formaldehyde treatment (O. Kistner et al idem ... 		10/02/2008
1      
 
Forgot password?
Register here